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Abstract Clinical risk factors have a low predictive value on
suicide. This may explain the increasing interest in potential
neurobiological correlates and specific heritable markers of
suicide vulnerability. This review aims to present the current
neurobiological findings that have been shown to be implicat-
ed in suicide completers and to discuss how postmortem
studies may be useful in characterizing these individuals. Data
on the role of the main neurobiological systems in suicidality,
such as the neurotransmitter families, hypothalamic–pitui-
tary–adrenal axis, neurotrophic factors, and polyamines, are
exposed at the different biochemical, genetic, and epigenetic
levels. Some neuroanatomic and neuropathological aspects as
well as their in vivo morphological and functional neuroim-
aging correlates are also described. Except for the serotonin-
ergic system, particularly with respect to the polymorphism of
the gene coding for the serotonin transporter (5-HTTLPR) and
brain-derived neurotrophic factor, data did not converge to
produce a univocal consensus. The possible limitations of
currently published studies are discussed, as well as the scope
for long-term prospective studies.
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Introduction
Worldwide, more people die by suicide every year than by
homicides and in all wars combined [S1]. The estimated
global burden of suicide is a million deaths per year,
representing a mortality rate of 14.5 deaths per 100,000
habitants per year [1, S2].
Suicide has been variously defined in the literature and
the standardization of its nomenclature is being debated
[S3], notably for aspects referring to intentionality [S4]. A
widely utilized definition describes suicide as a “fatal self-
inflicted self-destructive act with explicit or inferred intent
to die” [S5]. In forensic medicine, to distinguish suicide
from deaths due to other circumstances, three main compo-
nents are considered: (1) death as the result of injuries,
poisoning, or suffocation; (2) self-inflicted; and (3) inten-
tionally inflicted [S3]. These operational criteria, however,
present some limitations, and considerable variability has
been observed in the way in which medicolegal experts
define a person who committed suicide [S6–S9].
Suicide (also called suicide completion) represents a com-
plex phenomenon, placed at the extreme of a continuum of
behaviors commonly referred to as suicidal behaviors (SB)
which also includes suicide attempt and suicidal ideas [2, S4].
A suicide attempt, or nonfatal SB, is “a potentially self-
injurious behavior with a nonfatal outcome, for which there
is evidence (either explicit or implicit) that the person intended
at some level to kill himself/herself; a suicide attempt may or
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may not result in injuries” [S3]. However, suicide attempters
and suicide completers only share a part of the underlying
etiological and neurobiological mechanisms and suicide com-
pleters are considered a more homogeneous group than sui-
cide attempters [2].
Risk factors for suicide can be categorized as distal and
proximal factors [2, 3]. Distal risk factors include family history
of suicide and genetic loading, early life adversities and epige-
netic modifications, personality traits, and cognitive styles [2,
3]. Family history of suicide is thought to be partially indepen-
dent from familial clustering of mental disorders [S10, S11].
The presence of early traumatic life events is considered as one
of the strongest distal risk factors for both suicide attempts and
suicide completion in adulthood [4, S12–S14]. Proximal risk
factors are represented by conditions that act as precipitants:
existence of psychiatric and/or physical disorders, psychosocial
crisis, recent life events conferring acute stress, and availability
of means [2, 3]. A number of sociodemographic factors can be
considered to be moderators of the relationship between distal
and proximal risk factors [2], such as gender, age, education,
religious and spiritual beliefs, family structure, employment
and income, social support, and quality of social environment
[5, S15–S18]. The relation between neurobiological risk fac-
tors and stressors has been described in some explanatory
models [S19], such as the stress–diathesis model [6, S20,
S21]. In this model, hopelessness, impulsivity, and aggression
are components of the diathesis for SB.
Despite the existence of these numerous clinical risk fac-
tors, none actually help to define who will die by suicide or
not. The low predictive value of clinical risk factors for suicide
completions may explain the increasing interest in investigat-
ing potential neurobiological correlates and specific heritable
markers of suicide vulnerability. Association mapping and
family, twin, and adoption studies strongly suggest heritability
to suicide. Genetic studies conducted to date have mainly
focused on the serotonin (5-HT) system and identified some
related candidate genes [S4, S22]. Several other genes have
been highlighted either through genome-wide association or
microarray studies with more or less satisfactory results
[7–10, S23–S28]. Finally, the search for biological correlates
of suicide has more recently been expanded by epigenetic as
well as exome sequencing and microRNA studies [7–10,
S23–S29] (see Glossary [S30]).
The aims of the present review are to present the main
current neurobiological aspects that have been shown to be
implicated in suicide completion and to discuss how postmor-
tem studies may be useful in characterizing these individuals
and how they may contribute to helping the medical expert to
determine the circumstances of death, namely, if suicide is
suspected. In this respect, findings on the role of the neuro-
transmitter systems, hypothalamic–pituitary–adrenal (HPA)
axis, neurotrophic factors, and polyamines will be discussed
at the different biochemical, genetic, and epigenetic levels
(Table 1). A final section will be dedicated to neuroanatomic
and neuropathological data in suicide completers (Fig. 1) as
well their correlates to in vivo structural and functional imaging
results.
Neurotransmitter systems
Serotonin
5-HT is assumed to play a major role in the neurobio-
logical basis of SB. Indeed, 5-HT system alterations are
known to be part of the neurobiological diathesis of
suicide mentioned previously [6]. Abnormalities in this
system have been found in the prefrontal cortex (PFC),
hypothalamus, and brainstem of suicide victims (inde-
pendently of a history of mood disorder), especially in
the ventral prefrontal cortex (VPFC) [11, S31–S33].
Low levels of 5-hydroxyindoleacetic acid (5-HIAA), the
main 5-HT metabolite, in cerebrospinal fluid (CSF) have
been found in persons who had made a violent suicide
attempt [S34]. It has been suggested that low CSF 5-HIAA
is specific to suicide as it was found only in suicidal patients
[12]. It has been postulated that this biochemical trait may
be considered a predictor of suicide attempts and comple-
tions; it is consistent with low postmortem brainstem levels
of 5-HIAA in suicide victims [6]. It has also been shown
that patients with a history of high-lethality suicide attempts
had a blunted response to fenfluramine, an indicator of
central 5-HT activity through prolactin secretion, indepen-
dently of the comorbid psychiatric disorders [S35].
These findings have induced molecular genetic studies to
focus on 5-HT-related genes in search of genetic markers of
suicide. Tryptophan hydroxylase 1 (TPH1), tryptophan hy-
droxylase 2 (TPH2), and 5-HT transporter (5-HTT; SLC6A4)
genes have received the most research attention [13, S36, S37].
Two different isoforms of TPH, the rate-limiting enzyme in the
biosynthesis of 5-HT, are located on two different chromo-
somes. TPH1 is located on chromosome 11 and is responsible
for peripheral 5-HT generation, while TPH2 is known as the
brain-specific isoform and is located on chromosome 12 [S38].
Initially, studies of postmortem brains of suicides found no
evidence to support the involvement of TPH in suicide: no
difference in TPH immunoreactivity emerged between suicide
victims and controls, even when investigating specific
subnuclei of the dorsal raphe [S39]. More recently, in contrast,
TPH immunoreactivity was found to be higher in the dorsal
raphe nucleus of suicide victims, as a possible compensatory
mechanism to balance the diminished 5-HT activity [S40].
Higher levels of THP2 mRNA were found in the dorsal and
raphe nucleus of drug-free suicide subjects [S41]. Several poly-
morphisms in THP1 have been associated with suicide attempt,
but to our knowledge, none have truly been implicated in
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suicide completion [11].More promising results were found for
TPH2. Studies on single-nucleotide polymorphisms (SNPs or
SNIP) and haplotypes of TPH2 have been carried out and a link
between TPH2 and suicide has been demonstrated [S42]. In
support of these findings, TPH2 mRNA levels in the VPFC of
suicide completers were found to be increased and a specific
SNIP in the promoter region of TPH2 (rs-10748185) has a
significant effect on TPH2 mRNA expression [13]. These data
are consistent with previous findings, indicating a greater
amount of TPH2 mRNA in the raphe nuclei and in the DLPFC
of suicide victims [S43, S44]. The TPH2 gene at least certainly
is a promising subject which deserves further investigation in
order to explain better its role in SB.
The SLC6A4 gene, which codes for the 5-HTT and plays a
pivotal role in the regulation of 5-HT activity, has a common
polymorphism (5-HTTLPR) in a regulatory region which leads
to the presence of a short allele (S-allele) and a long allele (L-
allele) [S45]. Several studies have shown fewer presynaptic 5-
HTTsites in suicide victims, especially in the VPFC, regardless
of mood disorder diagnoses [11, 12, S32, S33]. The first studies
to investigate a possible relation between 5-HTTLPR and 5-
HTT binding showed no significant association either in the
PFC [S33] or in the periphery (platelets) [S46]. Despite these
results, the S-allele seems to be associated with impulsive
aggression and SB [14, S47]. Moreover, a relation between
S-allele and violent suicide attempts [S48] and violent suicide
methods [S49] has been highlighted; thus, the presence of at
least one S-allele has been proposed as a predictor for SB [11].
A robust association between S-allele and SB has been shown
in two meta-analyses [S50, S51].
Table 1 Overview of the main findings in suicide completers at the
biochemical, genetic, and epigenetic levels
Authors
Proteins
5-HIAA [6, 12, S34]
5-HTT [11, 12, S32, S34]
5-HTR-1A, 5-HTR-2A [S31, S52, S53, S58]
AMPA receptors [S64]
μ-Opioids receptors [S68, S69]
CRH [S78]
BDNF [20, 23, S82, S85]
TrkB [S82, S89]
NT-3 [S85]
PKA, PKC [S91–S94]
CREB [S95, S96, S98]
PKB/akt [21, S99]
GSK-3β [S99]
PI3K [21]
PTEN [21]
QKI [S119]
Α2-adrenergic receptors [11, S65]
mRNA
5-HTT/SLC6A4 mRNA [13]
5-HTR-2A mRNA, 5-HTR-2C mRNA [S58]
TPH1 mRNA,TPH2 mRNA [13, S38, S41, S43]
CRH mRNA [S74, S75, S78, S79]
CRH receptor mRNA [S77, S80]
POMC mRNA [S75]
GR mRNA, GR1F mRNA [18]
GR1B, 1C, 1H mRNA [19]
BDNF mRNA [S82]
TrkB mRNA [S82]
PKA mRNA [S93, S94]
CREB mRNA [S96, S98]
P11 mRNA [22]
SSAT mRNA [S27, S104, S105]
QKI mRNA [S119]
microRNA [S29]
Candidate genes
5-HTT/SLC6A4 (5-HTTLPR) [11, S50, S51]
5-HTR-1A, 5-HTR-2A [S24, S52]
TPH1,TPH2 [13, S42, S44]
GABRA, GABA transporter [8, 9, S25, S26, S62, S63]
GR [18, 19]
BDNF [S82, S84]
TrkB, TrkB-T1 [S82, S84, S87, S88]
FGFR3, FGFR2 [7, S63]
CREB1 [S97]
SSAT [S27, S104, S105]
QKI [S119]
Table 1 (continued)
Authors
Multiple genes expression profiling
studies
[8–10, S23–S25, S27,
S122]
Epigenetic changes
GR, GR exon 1F [18, 19]
BDNF [20]
TrkB-T1 [S87, S88]
SSAT [24], S109
AMPA receptor ionotropic receptor for glutamate, BDNF brain-derived
neurotrophic factor, CREB cyclic AMP-responsive element binding,
CRH corticotrophin-releasing hormone, FGFR fibroblast growth fac-
tor, GABRA GABA receptor, GR glucocorticoid receptor, GSK-
3βglycogen synthase kinase-3β, 5-HIAA 5-hydroxyindoleacetic acid, 5-
HTR-1A, 5-HTR-2A, and 5-HTR-2C serotonin receptors, 5-HTT serotonin
transporter, 5-HTTLPR polymorphism of the HTT/SLC6A4 gene, 5-
HTT/SLC6A4 gene serotonin transporter gene, NT-3 neurotrophin-3,
P11 P11 protein, PI3K phosphatidylinositol 3-kinase, PKA protein kinase
A, PKB/Akt protein kinase B, PKC protein kinase C, POMC
proopiomelanocortin, QKI oligodendrocyte-specific RNA binding pro-
tein, SSAT spermidine/spermine N1 -acetyltransferase 1, TPH1 and TPH2
tryptophan hydroxylase 1 and 2, TrkB tyrosine receptor kinase type B,
TrkB-T1 tyrosine receptor kinase type B variant T1
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Reduced 5-HT neurotransmission in SB may also be rec-
ognized through 5-HT receptor (5-HTR) studies. Postsynaptic
upregulation of 5-HTR-1A and 5-HTR-2A in the PFC of
suicide victims has been demonstrated. This upregulation
may be explained as a compensatory response to the low
activity of 5-HT neurons [S31], but it is also assumed to be
at least partially genetically regulated [S52]. In particular, an
increase in 5-HTR-2A binding in Brodmann areas 8 and 9 was
found in suicide victims [S31] and there is evidence for the
upregulation of 5-HTR-2A in the prefrontal Brodmann areas
in suicide brains [S53] as well as in peripheral tissues (plate-
lets of suicide attempters) [S54]. A polymorphism of 5-HTR-
2A gene (T102C A) has been associated with suicidal ideation
in patients with major depression and it seems that it might
confer increased risk of SB [S55], whereas data on the 5-HTR-
2A polymorphism are still being debated [S56, S57]. Never-
theless, higher 5-HTR-2A mRNA levels were found in the
PFC and the hippocampus of teenage suicide victims [S58].
Another 5-HTR-2A gene polymorphism (A1438G) has been
widely investigated for an association with SB, but no reliable
result has emerged, especially for suicide completion [S39,
S59]. No association between 5-HTR-1B gene polymorphisms
and suicide has been detected [S60]. Regarding 5-HTR-2C,
alterations in pre-mRNA editing and expression may be found
in receptors in the PFC of suicide victims [S58]. Investigation
of the variations in genes coding for 5-HTR 1Dα found no
differences in allelic or genotypic distributions between suicide
completers and controls [S61].
Other neurotransmitters
Dysregulated expression of GABAergic genes has been found
in suicide completers. Altered expression of several GABA
receptor subunits was demonstrated in PFC and limbic brain
regions. GABA-A receptor-associated protein like 1
(GABARAPL1) showed alterations in gene expression, as well
as GABA transporter (SLC6A1) [8, 9, S25, S26, S62, S63].
A study on NMDA receptors, a type of ionotropic gluta-
mate receptor, showed no difference in glutamate receptors
between suicide and control subjects. The density of AMPA
receptors, another type of ionotropic glutamate receptor,
may be increased in the caudate nucleus of suicide subjects
[S64]. Glutamatergic genes were found to be altered in
mood disorders, but independently of suicide [S62].
Fig. 1 Main neuroanatomic regions investigated in human brains of
suicide completers. a Schematic human brain, sagittal section; b
9chematic human brain, external view. PFC prefrontal cortex [10, 15,
21, 22, S23, S25, S29, S31, S53, S58, S63, S76, S82, S91–S93, S98,
S110], VPFC ventral prefrontal cortex, including the orbitofrontal
cortex [8, 11–13, S33, S37, S85, S87, S88, S95, S99, S104, S105],
DLPFC dorsolateral prefrontal cortex [10, 24, 26, S43, S108, S109],
Wernicke’s area [20, S89], Hippocampus [18, 19, S58, S82, S85, S91,
S94, S96, S98, S110, S111], Amygdale [S122], ACC anterior cingulate
cortex [10, 25, S25, S120, S121], Limbic system hippocampus, amyg-
dala, ACC, and posterior cingulated cortex (PCC) [S25], Nucleus
accumbens [10], LC locus coeruleus [7, S78], MRN median raphe
nucleus [S41, S78], DRN dorsal raphe nucleus [S40, S41, S43, S44],
PVN hypothalamic paraventricular nucleus [S73, S74], NC nucleus
caudatus [S64]. Some authors have not been specified in this diagram
because they examined several brain regions [S26, S27, S79]
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Adrenergic transmission has been hypothesized to play a
role in suicide. The main findings related to the decreased
noradrenalin levels in the brainstem and increased α2-
adrenergic receptor densities due to a noradrenaline deficit
[11]. Abnormalities in α2-adrenergic signaling pathways,
possibly associated with factors affecting the G protein
cycle, were found in the frontal cortex of depressed suicide
victims [S65].
In spite of the dopaminergic theory of mood disorders,
there is very little evidence to implicate dopaminergic trans-
mission in suicide and no significant difference in the mea-
surements of dopamine (DA) concentrations in the cortical
and subcortical regions in suicide victims versus controls
has been found [S66]. The presence of DA D2 receptors
might confer a risk of SB in patients with high familiar
loading for alcoholism [11]. Anyway, this circuit deserves
more investigation, as the significant reduction in DA trans-
port coupled with the observed increase in D2/D3 receptors
in the amygdale of subjects with major depressive disorder
(MDD) and regional changes in dopaminergic transmission
may be involved in mood disorders and suicide [7].
At present, there is no evidence to suggest a change in
cholinergic activity in suicide [7]. No significant difference
in muscarinic receptor (mAChRs) activity was found in
suicide brains [S67].
The relationship of opioids with suicide was first studied
in quantitative autoradiography studies. A higher density of
μ-opioids receptors was found in the frontal and temporal
cortex in younger suicide completers [S68]. This result was
confirmed later by the same technique [S69]. Nevertheless,
this topic remains to be investigated, as no difference in μ-
opioid density or affinity has been found in the PFC and
precentral–postcentral gyrus of suicide completers [15].
Hypothalamic–pituitary–adrenal axis
The HPA axis represents the major biological infrastructure
of the human stress system, and its dysfunctions have been
investigated in depressed and suicidal patients [2, 7, S58].
Whereas an association between cortisol nonsuppression at
the dexamethasone suppression test (DST) and suicide at-
tempt is still controversial [2, S70], cortisol nonsuppression
has been strongly associated with suicide completion. It seems
to be a useful predictor of suicide completion in depressed
subjects [16, S71]. DST nonsuppression emerged as a long-
term suicide predictor, while a low level of 5-HIAA in the CSF
was associated with short-term suicide risk [S72].
Postmortem studies have shown that hyperactivity of the
corticotrophin-releasing hormone (CRH) in the hypothalamic
paraventricular nucleus is a prominent feature in depressed
subjects and suicide completers [2], as suggested by increased
CRH neuronal counts [S73] and increased CRHmRNA levels
[S74]. Proopiomelanocortin mRNA is also higher in the pitu-
itary corticotropic cells of suicide victims than in controls
[S75]. Suicide completers also show reduced CRH binding
sites in the PFC [S76] and altered CRH receptor type I and
type II ratios in the pituitary gland [S77]. In depressed sui-
cides, augmented CRH immunoreactivity and CRH mRNA
levels [S78, S79] as well specific reduction of CRH receptors
(CRH1 but not CRH2) have been observed, possibly as a
consequence of the elevated CRH levels [S80].
There is increasing evidence that early life environment
influences reactivity to stress partly by epigenetic mechanisms
that regulate the activity of the genes involved in stress re-
sponse systems [2, 7, 17]. DNA methylation of the NR3C1
promoter of the glucocorticoid receptor (GR) exon 1F, de-
creased GR mRNA, as well as mRNA transcripts bearing the
GR 1F splice variant were found in the hippocampal tissue of
suicide victims with a documented history of childhood abuse,
whereas these patterns were not observed in suicide victims
without childhood abuse [18]. Consistent with the finding that
psychopathology has no effect [18], differences in 1F promoter
were not observed in the hippocampus of patients with MDD
without a history of childhood abuse who died by causes other
than suicide [S81]. The decreased NR3C1 glucocorticoid ex-
pression caused by the silencing activity of this methylation
results in hyperactivity of the HPA axis, which became
unresponsive to the negative feedback exerted by glucocorti-
coids. GR promoter methylation and differential GR exon 1B,
1C, and 1H expression have recently been observed in the
hippocampus of suicide completers with a history of childhood
abuse compared with suicides without a history of abuse and
with control subjects [19].
Neurotrophic factors
Neurotrophic factors, also called neurotrophins, represent a
family of extracellular signaling molecules well-known for
being implicated in neuronal proliferation, survival, and plas-
ticity. Many investigators have associated them with major
depression or suicide and it has been suggested that alterations
in their expression partly underlie the changes in plasticity
observed in the brains of suicide victims [2, 7]. In this review,
the possible role of brain-derived neurotrophic factor (BDNF),
tropomyosin-related kinase B (TrkB), a transmembrane recep-
tor binding to the BDNF, neurotrophin-3 (NT-3), and fibro-
blast growth factor receptors (FGFR) will be discussed.
Some studies in suicide completers, most of whom were
diagnosed with major depression, showed that BDNF and
TrkB were downregulated in different brain regions [S82–
S84]. Significantly decreased BDNF levels both in the hip-
pocampus and VPFC and decreased NT-3 in the hippocam-
pus, but not in the entorhinal cortex, were observed in
suicide victims who did not receive drug treatment [S85].
Int J Legal Med (2014) 128:73–82 77
The absence of change in BDNF and NT-3 levels in drug-
treated suicide victims may suggest that both neurotrophins
are mediators of psychotropic drugs [S85]. Receptors of
FGF (FGFR3 and FGFR2) were shown to be downregulated
in the PFC and multiple other brain regions of suicide brains
[7, S63].
Epigenetic studies in rats exposed to stress showed
hypermethylation of several exons in the promoter region of
BDNF, including exons IVand IX, compared to controls [S86].
After these data had been obtained in animals, a postmortem
study on brains from suicide completers found increased
BDNF promoter/exon IV methylation in Wernicke’s area
[20]. Although these results are consistent with some previous
BDNF findings from the rat model of early life adversity, a
history of childhood abuse was not examined in this study
however [2]. A variant of TrkB (TrkB-T1), mostly specific to
astroglial cells and with a role in calcium signaling, was
downregulated in the orbital frontal cortex of suicide com-
pleters in association with methylation at two sites in the
promoter, with no alteration in the two main TrkB variants
[S87, S88]. This methylation pattern may be specific to the
PFC because it was not observed in Wernicke’s area or in the
cerebellum [2, S89].
Other extracellular and intracellular cells signaling systems
Other extracellular signaling cascades and related intracellular
molecules, such as the phosphoinositide and adenylyl cyclase
signaling systems, have received attention in mood disorders
and suicide [7, 8, S58]. Postmortem studies in depressed
patients and suicide completers focused on the possible role
of protein kinase C (PKC) [S90–S92], protein kinase A [S93,
S94], cyclic AMP-responsive element binding protein [S95–
S98], protein kinase B (PKB, also called Akt) and glycogen
synthase kinase-3β (GSK-3β) [21, S99], and phos-
phatidylinositol 3-kinase (PI3K) and phosphatase and tensin
homolog (PTEN) [21]. A decrease in Akt and an increase in
GSK-3β were found in depressed suicide victims and
nonsuicide subjects showing an association with MDD rather
than with suicide [S99]. In the same way, in relation to PI3K
and PTEN, a decreased PI3K activity and increased protein
levels of PTENwere found in depressed subjects, regardless of
suicide [21]. A recent paper [22] focused on P11 protein, also
called S100A10, which is a regulator of a number of cellular
processes, on the basis of its documented association with
depression [S100] and posttraumatic stress disorder [S101,
S102]. P11 mRNA levels were significantly lower in the
peripheral blood mononuclear cells of suicide attempters and
in the PFC in suicide completers [22]. Several interactions
between these pathways as well as between the molecules
and neurotransmitter systems and genes that have been asso-
ciated with suicide exist, for example, the activation of tran-
scription factors by PKC results in the transcription of BDNF
[23]; PKB/akt represents a downstream effector of the 5-HT
system [S99], and 5-HT1B receptor function is altered by P11
in depression-like states [S100].
Polyamines
The function of polyamines in cells is not entirely clear, but it is
known that they play a role in cell stress system response and
their dysfunctions have been associated with psychopathology
both in human and animal studies [7, S103]. In suicide com-
pleters with or without major depression, spermidine/spermine
N1-acetyltransferase 1 (SSAT, also called SAT1 or SAT) ex-
pression has been shown to be significantly downregulated in
the VPFC [S104, S105] and other brain cortex regions [S27].
Several SNPs in SSAT have been associated with suicide in
French Canadians and specific haplotypes have been shown to
modify its expression [S104, S106, S107]. DNA methylation
at the promoter region of the SSAT gene has been shown to be
negatively correlated with its expression in suicide completers
[24, S108, S109]. A previous study, in contrast, observed no
epigenetic differences between suicide victims and controls
[S105]. Possible explanations for these discrepant results
may be differences in the psychiatric diagnosis of the subject
included, themajority ofwhomhad amajor depressive episode
[S109] versus a range of axis I disorders [S105] and examina-
tion of the DLPFC [S109] versus the VPFC [S105, S109].
Neuropathological data
Both postmortem genetic and neuropathological studies in
mood disorder patients and suicide completers have largely
focused on tissues obtained from the PFC, VPFC, including
the orbitofrontal cortex, and DLPFC or the limbic area (hip-
pocampus, amygdale, and cingulate cortex) [9, S110, S11]
(for a summary of the main neuroanatomic regions investigat-
ed in human brains of suicide completers, see Fig. 1).
Alterations of glial cells, especially astrocytes and oligo-
dendrocytes, have been investigated in major depression and
suicide [7]. A number of studies in depressed and suicide
completer subjects suggested that astrocyte levels were nor-
mal or increased in the depressed brain, with the possible
exception of younger suicides where a reduction in astrocytes
has been observed [S112–S115]. Dysfunction of astrocytes,
rather than reduction in cell number, was investigated through
microarray analyses for a number of astrocytic-specific genes
(i.e., Trkb.T1, FGFR2, FGFR3) [S63, S87, S88] (see the
“Neurotrophic factors” section). Given the role of glutamate
in mood disorder and the role of astrocytes in its metabolism,
astrocytes may be mediators of the glutamate dysfunction
detected in major depression and suicide [7, S116]. Hypertro-
phic astrocytes, with significantly larger cell bodies, as well as
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longer andmore ramified processes, were found in the anterior
cingulate cortex (ACC) of depressed suicides [25]. At the
same time, evidence of the dysfunction of astrocyte connexins
30 and 43 in the DLPFC of suicide completers was provided
[26]. This finding is consistent with a gene expression study
performed in the locus coeruleus of depressed subjects, most
of whom died by suicide [S116].
The hypothesis that oligodendrocyte dysfunctions play a
role in depression and suicide was suggested by some reports
which found a large number of oligodendroglial-specific
genes to be downregulated in the postmortem brain of de-
pressed subjects [S117–S119]. In the ACC, neuronal and glial
densities as well as neuronal soma sizes were unaltered in
depressed suicides compared to matched controls [S120]. A
robust increase in glial cell densities in alcohol-dependent
depressed suicides compared with non-alcohol-dependent de-
pressed suicides and controls was found instead [S120]. The
same group reported that, in the ACC of depressed suicides,
pyramidal neurons displayed altered dendritic branching, with
third-order branches significantly reduced in number [S121].
A final aspect of the neuropathologic discussion about the
neurobiology of SB concerns neurodevelopmental and
neuroplasticity issues [2, 27]. A haplotype of 14-3-3 epsilon,
a gene related to neurogenesis, was found to be associated with
suicide completion [S122]. Subventricular zone astrocytes are
neural stem cells in the adult mammalian brain and it has been
suggested that astrocytes play a role in the neurogenesis hy-
pothesis of depression [S123, S124]. Astrocytic-related dys-
functions observed in suicide completers [S63, S87, S88] could
influence astroglial growth, signaling, and differentiation [7]. In
the same way, the authors who showed alterations in dendritic
branching of pyramidal neurons [S121] speculated that this
difference may reflect a neurobiological predisposition to de-
pression and suicide given that proximal dendritic branches
grow during perinatal development and are generally less plas-
tic at maturity than the distal segments.
Neuroimaging correlates
In parallel with postmortem genetic and neuropathological
findings, both structural and functional neuroimaging studies
in SB focused on alterations in the PFC, particularly the VPFC
including the orbitofrontal cortex and DLPFC, the ACC, and
to a lesser degree, the amygdale [28, S125, S126]. The main
correlated neuropsychological traits consist in higher impul-
sivity, impaired decision-making, a particular attention to spe-
cific negative emotional stimuli, lower problem-solving
abilities, and reduced verbal fluency [28, 29, S125].
Most recent structural magnetic resonance imaging find-
ings showed a significantly thinner cortex in the VPFC,
DLPFC, and ACC in MDD patients at high risk for suicide
in contrast to non-high-risk patients [S127]. Specific gray
abnormalities in the same regions have been found to discrim-
inate attempter from non-attempter subjects and even to dif-
ferentiate high-lethality attempts from low-lethality attempts
among patients with borderline personality disorder [S128].
Another direction in morphological studies considers the
possible role of the white matter [28, S126]. A reduced size of
the posterior third of the corpus callosum, with a possible
diminished interhemispheric connectivity [S129], and a de-
creased fractional anisotropy in the left anterior limb of the
internal capsule [S130] have been found in patients with SB.
When these observations and the glia-related dysfunctions
discussed in the “Neuroimaging correlates” section are con-
sidered, it may be postulated that a relevant aspect of
suicidality neurobiology involves alterations in the glia and,
by extension, in the regions from which glial cells are derived
and in those regions which contribute fiber tracts [27].
Functional and pharmacological neuroimaging studies
have put particular emphasis on the importance of the PFC
and the amygdale, as well as their close relationships with
the serotoninergic system. Positron emission tomography
imaging showed a reduced activation of the medial PFC in
major depression patients with high-lethality versus low-
lethality suicide attempts [S131]. An increased binding of
the 5-HT transporter was found in the ACC of bipolar
patients with a history of suicide attempts compared with
those without a past history of attempts [S132]. Some stud-
ies combining neuroimaging and genetics suggested that the
brain regions involved in vulnerability to SB are modulated
by genetic polymorphisms previously associated with SB.
For instance, the 5HTTLPR variant seems to modulate the
activation of the medial PFC and amygdale during both the
resting state and aversive stimulation [S133, S134].
Concluding remarks
The value of investigating the neurobiological issues of
suicide consists in the potential for uncovering biomarkers
associated with suicide risk. A secondary aspect is the scope
for defining some potential biological hallmarks of suicide
that could help in determining the circumstances of death.
Concerning neurotransmitters systems, data remain globally
contradictory. The most interesting is the 5-HT system, partic-
ularly with respect to polymorphisms such as 5-HTTLPR.
Despite this, there is no evidence of specificity between a
polymorphism and its clinical expression. Among other neuro-
transmitters, more consistent data are provided only for GABA.
The opioid system represents a promising avenue.
To date, the possibility of utilizing results from postmortem
studies is mainly limited by the fact that they are not easily
generalized in living persons. At a theoretic level, potential
indices of suicide risk assessment in peripheral tissues obtained
from patients with SB may include the determination of
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epigenetic changes [20, 24, S8, S87, S88, S108, S109]. In
particular, epigenetic changes for both HPA axis and BDNF
with its receptor TrkB seem to be valid candidates for suicide
risk assessment. However, it appears to be difficult to ascribe
the observed differences specifically to suicide. Indeed, studies
in both animals and humans have indicated that these differ-
ences may be better explained by a deleterious environment
during childhood. The study conducted by McGowan et al.
[18], which shows that suicide subjects who did not suffer
childhood abuse do not present any patent change of the HPA
axis compared to controls, is an impressive demonstration of
this. Because of the important role played by the environment
—with not only distal but also proximal effects—more precise
and predictive studies on suicide should integrate robust envi-
ronmental measures, including the longitudinal assessment of
developmental factors [2, 7, S135].
Assay of BDNF in the serum [S124] or in peripheral blood
lymphocytes and platelets [S136] as well BDNFmRNA assay
in peripheral blood mononuclear cells [S136] may represent
other theoretical alternatives. The specificity of these indica-
tors, however, is largely limited in the previously mentioned
studies because of the significant overlapping with major
depression, the more important proxy of suicide risk. This
remark may also be generalized to other associations between
indices of low 5-HT neurotransmission and SB, which remain
unspecific [7]. In this context, long-term prospective studies
may be useful. The ideal design of these studies may consist in
evaluating two cohorts of patients affected by the same psy-
chiatric disorder, one with SB or suicide completion and the
other without. In addition, it has been suggested that other
environmental factors such as antidepressant drugs, which are
rarely taken into account in these studies, may substantially
modify the neurotrophin levels in postmortem brains
[S85]. Significant differences in BDNF and NT-3 levels
between suicide completers and controls were observed
only in those subjects who did not receive drug treatment
[S85]. This may prompt some reservations concerning the
pertinence of these indices to suicide risk assessment,
given that treated subjects will not be detected. P11 pro-
tein dosage in peripheral blood mononuclear cells may
constitute another alternative [22], but to date, this possi-
bility has been demonstrated in a single study only and
needs to be tested in other clinical settings.
Neuropathological data are scarce and not conclusive. An
important limitation may consist in the heterogeneity of the
clinical patterns included, which may be similar to that
discussed for the markers of neuropathological state applied
in other psychiatric diseases [S111, S137].
Moreover, the majority of postmortem studies present
some methodological limitations, i.e., small sample size or
a focus on a single or few brain areas with a relevant
influence on the significance of genetic and association
studies [S20, S26, S27, S79].
A recent very important direction in the domain of psychi-
atric genetic studies of suicide is the considerable interest
accorded to identifying the underlying dimensions that mediate
the relationship between genes and SB, the so-called interme-
diate phenotypes or endophenotypes [7, S138, S139]. A num-
ber of potential candidate biological and clinical
endophenotypes for SB have been identified, based largely on
association with the phenotype [S139–S141]. Among the
impulsive-aggressive traits, disadvantageous decision-making
has been suggested as a possible important endophenotype [29,
30, S141–S144]. They represent a very interesting field of
investigation in suicide studies, but also raise the problem of
exploring these dimensions in dead persons. In this context,
psychological autopsies may provide a relevant contribution.
In conclusion, despite the mass of data that has accumulated
to date which explores the interaction between the different
genetic, environmental, microstructural, and developmental
brain factors constituting the complexity of the suicide phe-
nomenon, no formal consensus exists in associating a neurobi-
ological mechanism with suicide. We are still some way from
determining a specific biologic abnormality, both in assessing
suicide risk and in providing an additional tool to medical
experts to correlate the cause of death with suspected suicide.
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Glossary of the main genetic terms contained in the text
[S30]
Allele: one of the different forms of a gene that can exist at a
single gene locus.
Association mapping: a method used for direct identifica-
tion of the specific genes (see candidate gene) that con-
trol the differences in phenotype among members of a
population.
Candidate gene: a gene that, because of its chromosomal
position or another property, becomes a candidate for a
particular function such as disease risk.
DNA methylation: the addition of methyl groups to
DNA residues after replication; it is a mechanism of gene
transcription regulation. It represents an important heritable
epigenetic mark (see epigenetic).
Endophenotype: quantifiable biologic or psychological vari-
able associated with genetic risk for a disorder; also named
intermediate phenotype.
Epigenetic: nongenetic chemical changes in histones or DNA
which alter gene function without altering the DNA se-
quence.
Exome sequencing: sequencing of a set of expressed regions
of genes (exons). It is performed only for rare SNPs.
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Gene locus the specific place on a chromosome where a gene
is located.
Genome-wide association (GWA): association mapping that
uses marker genes loci to scan the entire genome for genes
contributing to quantitative variation. It does not require an
a priori hypothesis on candidate genes.
Haplotype: the combination of alleles at multiple gene loci on
the same segment of homologous chromosomes.
Microarray study: analysis of an array of DNA frag-
ments representing all the genes in a genome. This
technique simultaneously examines the expression
levels of thousands of gene transcripts.
microRNA (miRNAs): a class of functional RNA that reg-
ulates the amount of protein produced by a gene; it represents
a mechanism of gene expression regulation (post-transcrip-
tional gene repression).
Phenotype: (1) The form taken by some character (or group of
characters) in a specific individual. (2) The detectable out-
ward manifestations of a specific genotype.
Polymorphism: the coexistence of two or more common phe-
notypes of a character.
Single-nucleotide polymorphisms (SNPs or SNIP): a nucle-
otide pair difference at a given location in the genomes of two
or more individuals. They represent the most prevalent types
of polymorphisms. Common SNPs: when the less common
allele occurs at a frequency of about 5 % or greater; rare
SNPs: when the less common allele occurs at a frequency
below 5 %.
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